An Alzheimer's therapy that retrains the immune system passed its first human trial

Instead of attacking the brain's plaques directly, Weizmann scientists tried a different idea: rejuvenating the aging immune cells that should be clearing them. The Phase I trial, reported in Nature Medicine, showed the approach is safe in people — the first human step for a treatment that works with the brain, not against it.